InflaRx NV (STU:IF0)
€ 2.022 0 (0%) Market Cap: 141.14 Mil Enterprise Value: 84.15 Mil PE Ratio: 0 PB Ratio: 2.04 GF Score: 38/100

Inflarx NV at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 05:30PM GMT
Release Date Price: €3.76 (+3.87%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. So welcome to the Thursday session of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.

Our next presenting company is InflaRx, and presenting on behalf of the company is CEO, Niels Riedemann. Niels?

Niels C. Riedemann
InflaRx N.V. - Co-Founder, CEO & Executive Director

Yes. Thanks so much, Anupam, for inviting us here. Good morning, everyone. I would also like to welcome those listening in on the webcast.

Before I start, I have to advise you that I will be making forward-looking statements and you know that there's disclaimers that come with that.

Now InflaRx is about C5a-inhibiting technology. We've dedicated about 20 years of research towards this goal, and we are the leading company in the anti-C5a space. We have drugs, 2 drugs, in development that are capable of completely and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot